Navigation Links
Nfocus Neuromedical, Inc. Luna™ Aneurysm Embolization System Receives CE Mark
Date:2/15/2011

PALO ALTO, Calif., Feb. 15, 2011 /PRNewswire/ -- Nfocus Neuromedical, Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, announced today that its Luna™ Aneurysm Embolization System (AES) received CE Mark for the treatment of patients with brain aneurysms.  The Luna AES is designed to be a single-deployment, easy-to-use system for the treatment of brain aneurysms both pre- and post-rupture.  

"Brain aneurysm treatment historically has been the domain of either surgery or, more recently, catheter-placed wire coils," said Eric Milledge, CEO, Nfocus Neuromedical.  "Surgery can be traumatic and expensive, and coils may fail to fully treat an aneurysm.  The Luna AES represents a dramatic step forward in the treatment of these patients."

It is estimated that up to one in 15 people will develop a brain aneurysm during their lifetime.(1)  Rupture of an aneurysm can cause stroke, brain damage and even death.

The Luna AES treats brain aneurysms by blocking (embolizing) blood flow while providing a scaffold to encourage tissue growth across an aneurysm opening and create a plug. The Luna uses a self-expandable, multi-layer oval implant made from Nitinol, a nickel-titanium alloy. The properties of the device allow it to easily compress within a conventional catheter, and then rapidly and easily open to full size once deployed within an aneurysm.

"CE Mark approval is an important milestone for Nfocus," said Robert O'Holla, vice president of regulatory affairs, Nfocus Neuromedical.  "The Luna AES is our flagship product and we look forward to working with physicians and hospitals in Europe to advance this important new technology."

About Nfocus Neuromedical, Inc.

Nfocus is developing the next generation treatment for brain aneurysms. The company's innovative LUNA™ product is a single-deployment, easy-to-use embolization device designed to be a direct replacement to detachable coils. Nfocus is backed by three major U.S.- and OUS-based venture funds: DFJ ePlanet Capital, Technology Partners, and InCube Ventures. Other investors include Raffles Capital and Endeavor Vision. More information can be found at www.nfocusneuro.com.

(1) - http://www.brainaneurysm.com/


'/>"/>
SOURCE Nfocus Neuromedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
2. Verathon(R) Helps Physicians Identify the Presence of Abdominal Aortic Aneurysms with New AortaScan(TM) Brand of Portable Ultrasound Aortic Measurement Instruments
3. Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment
4. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
5. Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms
6. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
7. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
8. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
9. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
10. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
11. Endovascular Forum and GEST Set Out on a Shared Venture to Bring the Highest Level of Embolization-based Scientific and Technical Education, Results, and Relevance for Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016  Nearly 30 million people in ... epidemic of diabetes. 1 However, nearly 40% of ... levels (hyperglycemia) and significant glucose variability. 2 These patients ... cardiovascular events. If left untreated, hyperglycemia can lead to ... or blindness. 3 As part of ...
(Date:12/6/2016)... Miss. , Dec. 6, 2016 Two ... rescue personnel in a simulated mass casualty event Tuesday ... . The technology debuted before an audience including ... and representatives from Homeland Security, Federal Law Enforcement ... Drone Project, known as HiRO (Health Integrated Rescue Operations), ...
(Date:12/6/2016)... JUPITER, Fla. , Dec. 6, 2016 With opioids ... a newcomer in the prescription drug market that has led to ... is approximately seven to eight times stronger than heroin or morphine, ... ... Suzanne Smolkin , vice president, clinical operations, Behavioral Health for ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... , ... December 07, 2016 , ... The medical profession ... and winter seasons. One major study analyzing heart attacks among 138,602 people recorded ... of a given year. We would all agree of course–no time of year is ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who believe ... hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, ... that you could reach out for, and grab, on the old carousels. If ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... fifth annual Business Architecture Innovation Summit in Reston, VA on March 21-22, 2017. ... will share a range of experiences from a cross-section of industries such as ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... have agreed to collaborate in developing a vaccine against the Middle East Respiratory ... vaccine can be available in South Korea for emergency deployment in the event ...
Breaking Medicine News(10 mins):